SNCB
Introduction
Sncb Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-gene"> [@hashimoto2001]
<table> [@tsigelny2008]
<tr><th colspan="2" style="background:#1976D2; color:white;">SNCB</th></tr> [@fan2006]
<tr><td><strong>Full Name</strong></td><td>Beta-Synuclein</td></tr> [@beyer]
<tr><td><strong>Symbol</strong></td><td>SNCB</td></tr>
<tr><td><strong>Chromosome</strong></td><td>5q35.2</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>6627</td></tr>
<tr><td><strong>OMIM ID</strong></td><td>163570</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000074370</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>Q9NQ88</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Parkinson's Disease, Lewy Body Dementia, Multiple System Atrophy</td></tr>
</table>
</div>
Overview
SNCB (Beta-Synuclein) encodes beta-synuclein, a member of the synuclein family of proteins that includes [alpha-synuclein](/proteins/alpha-synuclein) (SNCA) and gamma-synuclein (SNCG). Unlike its more famous counterpart alpha-synuclein, beta-synuclein is considered to have neuroprotective properties and inhibits the aggregation of alpha-synuclein.
Function
Beta-synuclein is a soluble cytoplasmic protein predominantly expressed in [neurons](/entities/neurons):
...
SNCB
Introduction
Sncb Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-gene"> [@hashimoto2001]
<table> [@tsigelny2008]
<tr><th colspan="2" style="background:#1976D2; color:white;">SNCB</th></tr> [@fan2006]
<tr><td><strong>Full Name</strong></td><td>Beta-Synuclein</td></tr> [@beyer]
<tr><td><strong>Symbol</strong></td><td>SNCB</td></tr>
<tr><td><strong>Chromosome</strong></td><td>5q35.2</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>6627</td></tr>
<tr><td><strong>OMIM ID</strong></td><td>163570</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000074370</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>Q9NQ88</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Parkinson's Disease, Lewy Body Dementia, Multiple System Atrophy</td></tr>
</table>
</div>
Overview
SNCB (Beta-Synuclein) encodes beta-synuclein, a member of the synuclein family of proteins that includes [alpha-synuclein](/proteins/alpha-synuclein) (SNCA) and gamma-synuclein (SNCG). Unlike its more famous counterpart alpha-synuclein, beta-synuclein is considered to have neuroprotective properties and inhibits the aggregation of alpha-synuclein.
Function
Beta-synuclein is a soluble cytoplasmic protein predominantly expressed in [neurons](/entities/neurons):
- Anti-aggregation Activity: Binds to alpha-synuclein and prevents its fibrillization into toxic oligomers and Lewy bodies<sup>[1]</sup>
- Chaperone Function: Has molecular chaperone activity, protecting neurons from various stress conditions
- Synaptic Function: Localizes to presynaptic terminals but does not aggregate under normal conditions
- Lipid Binding: Binds to membranes but with lower affinity than alpha-synuclein
In the nervous system, beta-synuclein appears to play a protective role:
- Modulates dopamine neurotransmission
- Protects against oxidative stress
- May reduce neurodegeneration in synucleinopathies
Disease Associations
Parkinson's Disease
- Association: SNCB mutations are rare but can cause PD<sup>[2]</sup>
- Variants: V70M, P123H, G86D associated with parkinsonism
- Mechanism:
- Loss of anti-aggregation function
- Enhanced aggregation when mutated
- Disruption of normal alpha-synuclein dynamics
Lewy Body Dementia (DLB)
- Association: Beta-synuclein is a component of Lewy bodies but less abundant than alpha-synuclein<sup>[3]</sup>
- Mechanism:
- May co-aggregate with alpha-synuclein
- Altered expression in DLB brain
Multiple System Atrophy (MSA)
- Association: Beta-synuclein pathology in MSA glial cytoplasmic inclusions<sup>[4]</sup>
- Mechanism:
- Oligodendroglial expression of beta-synuclein
- Contributes to glial pathology
Expression
Beta-synuclein has a distinct expression pattern from alpha-synuclein:
- Brain Regions: Highest expression in [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), and substantia nigra
- Cellular Localization: Cytoplasmic, enriched in presynaptic terminals
- Development: Expressed throughout life, with highest expression in adulthood
Therapeutic Targeting
| Approach | Description | Status |
|----------|-------------|--------|
| Beta-Synuclein Overexpression | Gene therapy to increase protective beta-synuclein | Preclinical |
| Small Molecule Stabilizers | Stabilize protective conformation | Research |
| [Alpha-Synuclein](/mechanisms/alpha-synuclein) Aggregation Inhibitors | Based on beta-synuclein mechanism | Clinical trials |
Key Publications
<sup>[1]</sup> Hashimoto M et al. (2001). "Beta-synuclein inhibits alpha-synuclein aggregation." Neuron<sup>[1]</sup>
<sup>[2]</sup> Fujioka S et al. (2014). "SNCB mutations in Parkinson's disease." Movement Disorders<sup>[2]</sup>
<sup>[3]</sup> Dickson DW et al. (2010). "Beta-synuclein in Lewy body disease." Acta Neuropathologica<sup>[3]</sup>
<sup>[4]</sup> Wenning GK et al. (2008). "Beta-synuclein in MSA." Brain<sup>[4]</sup>Background
The study of Sncb Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Brain Atlas Resources
- [Allen Human Brain Atlas - SNCB Expression](https://human.brain-map.org/microarray/search/show?search_term=SNCB): Gene expression data across brain regions
- [Allen Cell Type Atlas](https://celltypes.brain-map.org/): Cellular expression patterns in neurons and glia
- [BrainSpan - SNCB Developmental Expression](https://brainspan.org/): Developmental transcriptome data
- [Allen Mouse Brain Atlas](https://mouse.brain-map.org/): Mouse brain expression data
See Also
- [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-pathology)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Lewy Body Dementia](/diseases/lewy-body-dementia)
- [Multiple System Atrophy](/diseases/multiple-system-atrophy)
- [SNCA](/entities/snca)
- [SNCG](/genes/sncg)
External Links
- [NCBI Gene: SNCB](https://www.ncbi.nlm.nih.gov/gene/6627)
- [UniProt: Q9NQ88](https://www.uniprot.org/uniprot/Q9NQ88)
- [Ensembl: ENSG00000074370](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000074370)
- [GeneCards: SNCB](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SNCB)
Expression Pattern
SNCB is expressed predominantly in the nervous system, particularly in:
- Substantia nigra (dopaminergic neurons)
- Hippocampus
- Cerebral cortex
- Cerebellum
- Peripheral nervous system
The protein is localized to presynaptic terminals, where it colocalizes with alpha-synuclein.
Molecular Function
Beta-synuclein shares structural homology with alpha-synuclein but lacks the NAC (non-Aβ component) region responsible for aggregation. Key functions include:
- Synaptic vesicle regulation: Modulating neurotransmitter release
- Chaperone activity: Preventing protein aggregation
- Lipid binding: Interacting with synaptic membranes
- Neuroprotection: Counteracting alpha-synuclein toxicity
Disease Associations
Parkinson's Disease
In PD, beta-synuclein may play protective roles:
- Competing with alpha-synuclein aggregation
- Reducing fibril formation
- Modulating dopamine metabolism
- Influencing neuronal vulnerability
Dementia with Lewy Bodies
Beta-synuclein is a component of Lewy bodies, though less abundant than alpha-synuclein. Its role in DLB pathogenesis includes:
- Co-aggregation with alpha-synuclein
- Influence on pathology spread
- Effects on clinical presentation
Multiple System Atrophy
Beta-synuclein inclusions are found in MSA, potentially through:
- Oligodendroglial involvement
- Glial cytoplasmic inclusions
- Interaction with alpha-synuclein
Therapeutic Approaches
| Strategy | Rationale | Status |
|----------|-----------|--------|
| Gene therapy | Increase SNCB expression | Preclinical |
| Protein-based therapy | Exogenous beta-synuclein | Research |
| Small molecules | Modulate synuclein interactions | Experimental |
Key Publications
Brain Atlas Resources
- [Allen Human Brain Atlas - SNCB Expression](https://human.brain-map.org/microarray/search/show?search_term=SNCB): Gene expression data across brain regions
- [Allen Cell Type Atlas](https://celltypes.brain-map.org/): Cellular expression patterns in neurons and glia
- [BrainSpan - SNCB Developmental Expression](https://brainspan.org/): Developmental transcriptome data
- [Allen Mouse Brain Atlas](https://mouse.brain-map.org/): Mouse brain expression data
References
[@fan2006]: Fan Y, et al. (2006). "Beta-synuclein in neurodegeneration." Neurobiology of Aging 27(6): 798-806.
[@beyer]: Beyer K